INDUSTRY PARTICIPATION MANUAL

Industry Program Onboarding and information

Please liaise directly with your nominated speakers and chairs to confirm their availability and requirements.

All speakers and chairs must be registered to be able to attend and present at the session. You can use one of your sponsorship or KOL complimentary registrations to register your speaker for free or you can purchase additional registrations.

If you are not sure what registration type is more suitable for your speakers, please contact us

Naz Barootian
Sponsorship Relations Manager
sponex@aplarcongress.com

Onboarding Form

Please complete industry program onboarding form as required by the deadline indicated in the checklist and deadlines. Failure to do so may result in our inability to provide the appropriate service/s and may result in additional fees.

DEADLINE: 12 May 2021

You will be required to provide:

Session title
Synopsis
Format of presentation e.g.
- 10:20 – Introduction (5 mins)
- 10:25 – Speaker 1 (15 mins)
- 10:40 – Speaker 2 (15 mins)
- 11:55 – Speaker 3 (15 mins)
- 11:10 – Q&A (25 mins)
Location of presentation (live in Kyoto or virtually)
Chair name and contact details (including bio and photo)
Presenter name and contact details (including bio and photo)

You will be able to submit a partly completed form and log back in at a later stage to update or add more information. Minimum requirement for 12 May 2021 includes: Session title, location of presentation, presenter and chair photo and bio. The rest of the information should be provided by 1 June 2021.

If you require any assistance with this, please contact us.

Naz Barootian
Sponsorship Relations Manager
sponex@aplarcongress.com

Signage placement guidance for industry program

You can bring free-stand banners for the duration of your session. Please advise if you are bringing any signage with you. Outside of room: two (2) hours prior to your session starting, you are permitted to place one (1) pull up banner (850 x 2010mm) directly outside of your session room. This must be removed 15 minutes prior to the end of your session.

Pull Up Banner Size: 850 x 2000mm

You can provide marketing materials to the Industry Symposium attendees for your session when they are entering the session. Any marketing materials not taken by the attendees must be cleared from the room by the Industry Partner before the close of the Industry Symposium. Seat drops are not available. Please note that no flyer distribution or solicitation of delegates may take place for your industry program symposia or workshops outside the confines of your exhibition booth.

AV Specifications

The following AV is included in the standard package:

One (1) room screen
Projector set at 16:9 ratio
Lectern and lectern microphone

Additional AV may be hired, please include your interest in specific requirements in your industry program portal.

Speaker Preparation

ALL presentations, regardless of virtual or in-person, need to be pre-recorded and submitted to the congress organisers by the specified date. If you have in-person presenters they can still present live however the pre-recorded content will be used as a back up for virtual attendees in the case of technical faults on the day of presentation.

In-person speakers

In-person speakers will submit their pre-recorded presentation by the due date listed on this document. This pre-recording will only be used if the facilities fail on the day and the virtual attendees cannot access the in-room stream link.
On the day of presentation, speakers will need to submit their presentation slides onsite to our speaker preparation room where you will be able to go through the slides and rehearse with your speakers.
Room setup (schematic by room)
All times listed include set-up, presentation and pack up time. Pre-presentation room access may be available for some timeslots and subject to agreement with the APLAR 2021 Secretariat.

Virtual speakers

Virtual speakers will submit their pre-recorded presentation by the due date listed in this document. This presentation will be played to the virtual attendees and the in-person attendees in Kyoto simultaneously. Virtual speakers will then join the zoom link for the live Q&A that will be streamed to the Kyoto convention centre and the virtual platform.
The zoom links will be sent to the virtual speakers 7 days prior to the congress commencement.

Green room/Zoom room

The green room (zoom link) is open just (approximately 10- minutes) prior to the session commencement. The speakers/moderators will have their audio and visual tested by the technician located on the zoom room. The technician will provide instruction to the speakers prior to going live to the Kyoto and virtual attendees.

Q&A

Questions will be submitted through the virtual platform by in-person delegates and virtual delegates. These will then be read out by the chairperson.

The industry program is now available via our website at: www.aplar2021.com/industry-program. Please note program times may be subject to change.

QR Code Scanning - In Person

All exhibitors and industry program sessions will receive an individual QR code to enable delegates to scan into your booth.

The QR code may be scanned with the delegate’s phone through the APLAR 2021 congress app.

This QR code will be sent upon receipt of payment. We suggest you incorporate this into your booth design for maximum engagement.

The following information will be distributed.

Delegates will be scanned upon entry into the workshop/symposium room
Reports will be distributed in Excel format to partners by end of day
Exhibition booth scanning data will be distributed post congress
These reports will include name, organisation, email and country

Industry Program Promotion

All industry symposia are included in secretariat led promotion of the industry program, through a dedicated EDM.

Dedicated Industry Program Promotion - #1

Content: 3 months to Congress
Date: 25 May 2021

Dedicated Industry Program Promotion - #2

Content: 2 months to Congress
Date: 28 June 2021

Dedicated Industry Program Promotion - #3

Content: 1 month to Congress
Date: 27 July 2021

Full industry program published with times and dates and industry partner logos.
Symposium title included.
Links to APLAR 2021 Industry Program page on the website.

If we have not received the information noted above by the stated deadline, your items will not be included.

Atulya Deodhar

Oregon Health & Science University

United States

Atul A. Deodhar, MD, is Professor of Medicine and Medical Director of rheumatology clinics at the Division of Arthritis & Rheumatic Diseases in Oregon Health & Science University, Portland. He is Board Certified in Internal Medicine and Rheumatology; and is a fellow of the American College of Rheumatology, and also American College of Physicians.

Dr. Deodhar is a past-chair of SPARTAN (Spondyloarthritis Research and Treatment Network), an organization of North American Rheumatologists dedicated to education and research in the field of axial spondyloarthritis. He serves on the Steering Committee of GRAPPA (Group for the Research and Assessment of Psoriasis and Psoriatic Arthritis). He served on the American College of Rheumatology’s (ACR) treatment guidelines sub-committee, and as the associate editor of the Advanced Rheumatology Course by Association of Health Professionals in Rheumatology (ARHP). He has served the ACR in various other capacities as a vice chair of the annual meeting planning committee, member of the peripheral MRI task force, Association of Rheumatology Health Professionals (ARHP) nominating committee and developer of the ARHP online advanced rheumatology course. Dr. Deodhar serves on the Rheumatology Board of the American Board of Internal Medicine (ABIM)

Dr. Deodhar is the Editor-in-Chief of Best Practice and Research Clinical Rheumatology, and has been a guest editor for Current Opinion in Rheumatology. He is a reviewer for the New England Journal of Medicine, Lancet, Arthritis & Rheumatology, Annals of the Rheumatic Diseases, Annals of Internal Medicine, among several other journals. His research interests are axial spondyloarthritis, and psoriatic arthritis. He has authored 3 books, over 250 peer-reviewed articles; several book chapters, and editorials. Dr. Deodhar has been He has been a principal or co-investigator in more than 100 clinical trials, mostly focused on therapies for ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis.

He completed his fellowship in rheumatology at Oregon Health & Science University, and before that, a research fellowship in rheumatology at the Royal Cornwall Hospital, Truro, England. He completed his residency in internal medicine and geriatrics at the Royal Cornwall Hospital, Truro, as well as in the Sassoon General Hospital and King Edward Memorial Hospital, Pune, India. He received his MBBS and MD degrees from the University of Pune, India; and the MRCP from the Royal College of Physicians, London, England.

Md Mujibur Rahman

Bangabandhu Sheikh Mujib Medical University

Bangladesh

Professor Md. Mujibur Rahman is a renowned Internist recently joined to BSMMU as the Professor of Internal Medicine after serving Dhaka Medical College Hospital (DMCH) as professor and Head of Medicine. Under the leadership of Prof Rahman, the COVID-19 unit of DMCH was the largest dedicated COVID-19 hospital in the country. He and his team ran different research project in DMCH including several clinical trials. He is also one of the investigators of the SOLIDARITY trial of WHO in Bangladesh. He served different public medical college as faculty and proved himself as a great teacher, researcher and a humanely physician.

For his deep interest in Rheumatology, he used to run a Rheumatology Clinic which is giving services to hundreds of patients each week. He was the Principal Investigator of ShSMCH site for an international drug trial on Lupus Nephritis. He was the principal investigator of first STEP-wise survey of NCDs risk factors in Bangladesh in 2010. He took leadership in managing Dengue and Chikungunya outbreak in Dhaka during the time of crises.

Prof. Md. Mujibur Rahman was born in Gazipur, near Dhaka, in the year 1961. He has a very brilliant academic career as well as professional one. He did his HSC in 1977 and HSC in 1979 with distinction and stood 11th position in the combined merit list of Dhaka Board from Dhaka Residential Model school and college. He graduated from Dhaka Medical College in the year 1985 and joined the Government service of and completed FCPS in Internal Medicine in 1992 and MD Internal Medicine in 2001. He was awarded with International Fellowship Exchange Program of American College of Physicians as a first Bangladeshi Physician and he worked in rheumatology department of Massachusetts General Hospital in the year 2006.
Along with taking care of admitted patients, he is extensively involved in teaching and training programs. In his colourful professional career of 35 years, he has an enormous number of students and followers in home and abroad. He has over 60 publications in national and international journals and he presented over 50 papers in national and international seminars.

He is currently elected councillor of BCPS and was Honorary Controller of Examinations of the Bangladesh College of Physicians and Surgeons (BCPS), which is the number one postgraduate institute of the country.
Currently Prof. Md. Mujibur Rahman is the vice president of Bangladesh Rheumatology Society, Bangladesh Society of Medicine and Association of Physicians of Bangladesh. He is a Fellow of the American College of Physicians. He is the editorial board member of Bangladesh Journal of Medicine. He is trying to engage himself in improvement in the medical education, physicians’ training and research in Bangladesh.

Jeffrey Curtis

UAB Division of Clinical Immunology & Rheumatology

United States

Jeffrey R. Curtis, MD, MS MPH
Marguerite Jones Harbert – Gene V Ball, MD Professor of Medicine
Co-Director, UAB PharmacoEpidEmiology, and phaRmcoeconomics (PEER) Unit
Director, UAB Musculoskeletal Digital Health and Technology Laboratory
University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology

Dr. Jeffrey Curtis is a Professor of Medicine in the Division of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham (UAB). Dr. Curtis received a Medical Degree (MD) and a Master of Public Health (MPH) degree from Oregon Health & Sciences University in Portland, OR. He subsequently completed a residency in internal medicine at Oregon Health & Science University and a fellowship in rheumatology at UAB. He completed a graduate program in Clinical Informatics at Stanford University and received his Master of Science (MS) degree in epidemiology at the Harvard School of Public Health. He is board certified in both rheumatology and clinical informatics.

Dr. Curtis holds the Harbert-Ball Endowed Professorship in Rheumatology and Immunology at UAB. His major research emphasis is on evaluating the safety and comparative effectiveness of medications for rheumatic diseases. He also conducts both investigator-initiated and industry-sponsored clinical trials in rheumatoid arthritis (RA) and psoriatic arthritis (PsA), including large pragmatic trials. He is the Co-Director of the UAB Pharmacoepidemiology and Pharmacoeconomics Research (PEER) Unit. PEER uses multiple large and linked data sources to study comparative effectiveness questions across multiple chronic diseases. The data sources he routinely uses include national electronic health record, health plan claims (e.g. Medicare, commercial insurance), traditional registry, patient reported outcomes, mobile device, wearable technology; he has done numerous projects that link these disparate data sources together. In 2012, he was awarded the Henry Kunkel Young Investigator Award by the American College of Rheumatology (ACR) and was accepted into the American Society for Clinical Investigation (ASCI) in 2016. In 2015, Dr. Curtis was appointed as a member to the FDA Arthritis Advisory Committee, and also the CDC’s ACIP Herpes Zoster Working Group.

The evaluation of the efficacy, comparative effectiveness, and safety of the medications, devices, and other interventions (e.g. vaccines) used in the care of rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis patients. He served on the Core Expert Panel for the ACR’s 2008, 2012, and 2015 Recommendations for the Use of Nonbiologic and Biologic Disease Modifying Antirheumatic Drugs in RA. He was the Deputy Director for a collaborative project between the FDA, the Agency for Healthcare Research and Quality (AHRQ), and a number of academic centers studying the safety of biologic agents using multiple, pooled national data sources. He has served as the co-PI of the UAB Coordinating Center of the American College of Rheumatology’s (ACR) electronic health record-based registry Rheumatology Informatics System for Effectiveness (RISE) registry. RISE aggregates and normalizes EHR data from more than 3 million rheumatology patients, with data contributed by more than 1,000 rheumatology providers. He is the Co-PI of the mobile health-based, PCORI-funded Patient Powered Research Network “ArthritisPower” research registry, focused on RA, psoriasis, psoriatic arthritis, and Spondyloarthritis that has enrolled more than 30,000 patients.

Dr. Curtis also studies risk factors for and outcomes of osteoporosis. He was a member of the ACR’s task force to update recommendations for the management of glucocorticoid induced osteoporosis (GIOP). He served on the ASBMR Task Force on Atypical Subtrochanteric and Diaphyseal Fractures. In 2020, he was asked to serve on the ACR’s Vaccine Guideline Task Force, and he also leads the separate ACR COVID Vaccine Guidance Task Force.